Login to Your Account

In The Clinic NEWS

Jaakko Lappalainen, vice president of clinical development for Marinus Pharmaceuticals Inc., told BioWorld Today that early phase II success with ganaxolone against CDKL5 seizure disorder should not necessarily have taken anyone by surprise.

SHANGHAI – The Shanghai-based joint venture Wuxi-Medimmune has received the go-ahead to start clinical trials from Chinese regulators for anti-IL-6 antibody WBP216 (MEDI5117) as a therapeutic for autoimmune and inflammatory diseases, in particular rheumatoid arthritis (RA).

Dermira Inc.’s third positive phase III trial with Cimzia in moderate to severe psoriasis turned up “market-leading type” results at the 400-mg dose, the firm’s chief development officer, Luis Peña, told BioWorld Today.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: